Somewhat Positive Press Coverage Somewhat Unlikely to Impact Hemispherx BioPharma (HEB) Stock Price
News headlines about Hemispherx BioPharma (NYSE:HEB) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Hemispherx BioPharma earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 48.195739407841 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Hemispherx BioPharma (NYSE:HEB) traded up 1.562% on Friday, hitting $0.325. 377,387 shares of the stock traded hands. Hemispherx BioPharma has a 1-year low of $0.30 and a 1-year high of $1.24. The stock’s market cap is $9.48 million. The stock has a 50 day moving average of $0.35 and a 200-day moving average of $0.48.
Hemispherx BioPharma (NYSE:HEB) last released its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter. The firm had revenue of $0.21 million for the quarter. Hemispherx BioPharma had a negative net margin of 1,029.58% and a negative return on equity of 75.57%. On average, equities research analysts expect that Hemispherx BioPharma will post $0.00 EPS for the current year.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.